Author:
Aghajanian Carol,Bell-McGuinn Katherine M.,Burris Howard A.,Siu Lillian L.,Stayner Lee-Ann,Wheler Jennifer J.,Hong David S.,Kurkjian Carla,Pant Shubham,Santiago-Walker Ademi,Gauvin Jennifer L.,Antal Joyce M.,Opalinska Joanna B.,Morris Shannon R.,Infante Jeffrey R.
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference16 articles.
1. Morgensztern D, McLeod HL (2005) PI3K/AKT/Mtor pathway as a target for cancer therapy. Anti-Cancer Drugs 16:797–803
2. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR (2001) AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61:589–593
3. Bellacosa A, Testa JR, Moore R et al (2004) A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther 3:268–275
4. Altomare DA, Testa JR (2005) Pertubations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464
5. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, Zhao Z, Huber HE, Jones RE (2005) Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific AKT/PKB family members. Mol Cancer Ther 4:271–279
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献